Skip to main content
Clinical Trials/ITMCTR2100005248
ITMCTR2100005248
Not yet recruiting
未知

Research on reliability and validity and diagnostic efficacy evaluation of Qi Stagnation Syndrome and Its Subtype Syndrome Scale

Hunan University of Chinese Medicine0 sitesTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Hunan University of Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational study
Sex
All

Investigators

Sponsor
Hunan University of Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • (1\) Depression
  • 1\) Comply with the above\-mentioned Western medical disease diagnostic criteria (mild and moderate depression) and TCM syndrome diagnostic criteria;
  • 2\) 20 points \= Hamilton Depression Rating Scale (HAMD\-24\) total score \<35 points;
  • 3\) In line with the first episode of depression;
  • 4\) Patients with primary depression;
  • 5\) The vital signs are stable, conscientious, and expressive;
  • 6\) Those who have not taken Chinese or Western antidepressant drugs within 2 weeks;
  • 7\) 18 to 65 years old (including 18 and 65 years old), regardless of gender;
  • Only those who meet the above seven items at the same time can be selected.
  • (2\) Chronic non\-atrophic gastritis

Exclusion Criteria

  • (1\) Depression
  • 1\) Existence of schizophrenia or depression after schizophrenia;
  • 2\) There is evidence that there is a etiological relationship between depressive episodes and physical diseases;
  • 3\) Pregnant or breastfeeding women who belong to patients who have relapsed depression;
  • 4\) Non\-compliance with the inclusion criteria, or incomplete information affects the observer;
  • Those that meet one of the above will be excluded.
  • (2\) Chronic non\-atrophic gastritis
  • Exclude atrophic gastritis and special types of gastritis.
  • (3\) Perimenopausal syndrome
  • 1\) Patients with severe liver and kidney dysfunction or tumors;

Outcomes

Primary Outcomes

Not specified

Similar Trials